Eye injuries require immediate and effective treatment to prevent corneal opacification, neovascularization, irregularity and occasionally ulceration of the cornea, which can be potentially blinding. Eye injuries are generally treated with eye drops for 4-8 times per day, which may not be feasible in critically injured patients in intensive care. This research project aims to develop a nanowafer drug delivery system that can deliver the drug to the eye for longer periods of time to treat eye injuries and prevent potential loss of vision. During the third year of this project, dexamethasone loaded nanowafers have been fabricated and evaluated for the in vivo therapeutic efficacy in ocular burn induced mouse model. These studies revealed that the dexamethasone nanowafers are very effective in corneal wound healing and the suppression of corneal neovascularization as revealed by the laser scanning conofocal microscopy. The efficacy of the dexamethasone was also evaluated by PCR analysis. This study also revealed that once a week Dexamethasone nanowafer treatment is as effective as twice a day Dexamethasone eye treatment.